Drug Approval | January 24, 2026
Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India
Company to launch product after the expiry of semaglutide patent in India
Company to launch product after the expiry of semaglutide patent in India
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Subscribe To Our Newsletter & Stay Updated
